BioClever joins REVASCAT ischemic stroke trial

BioClever joins REVASCAT ischemic stroke trial
On April 17th, the Health Department of the Generalitat of Catalonia introduced the REVASCAT trial, which presented the conclusions on a new revolutionary treatment for ischemic stroke. 
BioClever participated in this interesting advance on ischemic stroke by performing eCRFs, data management and statistics.

The study lasted a little over two years, starting in November 2012 and concluding in December of last year, and has been developed in four Catalan hospitals: Vall de Hebron, Clínico, Bellvitge and Germans Trias, with the collaboration of the an> Polytechnic University of Catalonia (UPC) and the University of Pittsburgh (United States), and the participation of other international institutions to develop this clinical trial, a pioneer in the field of brain vascular pathologies. 
On this same day, a Catalan delegation that included part of the team of BioClever that participated in the study traveled to Glasgow (Scotland) to explain the results to the world at the European Stroke Organization Conference
The results from the REVASCAT trial have also been published in the renowned New England Journal of Medicine, in which the advantages of clearing the affected brain arteries in patients with stroke using next-generation devices introduced with microcatheters are explained. Thanks to this advance, the study concluded that patients affected by this condition and treated with this system have four times more chances to increase their autonomy during daily basic activities, allowing them to improve their quality of life as well as to increase the recovery of their functional capacity by 70%.

The procedure used in the study is highly complex, because it involves reaching very delicate areas of the brain by endovascular navigation and removing the thrombus through a catheter introduced in the femoral artery until the affected area is reached. That is why, it can only be performed in hospitals by highly qualified professionals. With this development, it will be possible to keep reducing the mortality rate of this condition that has such a significant social impact, since in Catalonia it is the first cause of death among women, the third among men, and the first cause of disability.  

Related news